Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nogapendekin alfa by ImmunityBio for Hepatocellular Carcinoma: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
Nogapendekin alfa by ImmunityBio for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Oral Cavity (Mouth) Cancer. According to...
Nogapendekin alfa by ImmunityBio for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer....
Nogapendekin alfa by ImmunityBio for Oropharyngeal Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase...
Nogapendekin alfa by ImmunityBio for Laryngeal Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase...
Nogapendekin alfa by ImmunityBio for Hypopharyngeal Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase...
Nogapendekin alfa by ImmunityBio for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
Nogapendekin alfa by ImmunityBio for Hereditary Nonpolyposis Colon Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Hereditary Nonpolyposis Colon Cancer. According to...
Nogapendekin alfa by ImmunityBio for Metastatic Colorectal Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Nogapendekin alfa by ImmunityBio for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
Nogapendekin alfa by ImmunityBio for Ovarian Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Nogapendekin alfa by ImmunityBio for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
Nogapendekin alfa by ImmunityBio for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...
Nogapendekin alfa by ImmunityBio for Solid Tumor: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Nogapendekin alfa by ImmunityBio for Hereditary Nonpolyposis Colon Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Hereditary Nonpolyposis Colon Cancer. According to...
Nogapendekin alfa by ImmunityBio for Metastatic Colorectal Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Nogapendekin alfa by ImmunityBio for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
Nogapendekin alfa by ImmunityBio for Ovarian Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Nogapendekin alfa by ImmunityBio for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Nogapendekin alfa by ImmunityBio for Pancreatic Cancer: Likelihood of Approval
Nogapendekin alfa is under clinical development by ImmunityBio and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...